Trials / Completed
CompletedNCT02857920
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.
Detailed description
By enrolling patients with recurrent solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Bevacizumab and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | 7.5 mg/kg, i.v, once every 3 weeks (continuous) |
| BIOLOGICAL | NK immunotherapy | Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-08-01
- Completion
- 2019-08-01
- First posted
- 2016-08-05
- Last updated
- 2020-09-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02857920. Inclusion in this directory is not an endorsement.